AU6968301A - Small technetium-99m and rhenium labeled agents and methods for imaging tumors - Google Patents
Small technetium-99m and rhenium labeled agents and methods for imaging tumorsInfo
- Publication number
- AU6968301A AU6968301A AU6968301A AU6968301A AU6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A
- Authority
- AU
- Australia
- Prior art keywords
- technetium
- tumors
- complexes
- methods
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 9
- 238000003384 imaging method Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 title abstract 2
- 229940056501 technetium 99m Drugs 0.000 title abstract 2
- 229910052702 rhenium Inorganic materials 0.000 title 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 title 1
- 201000001441 melanoma Diseases 0.000 abstract 2
- 150000003281 rhenium Chemical class 0.000 abstract 2
- 229910052713 technetium Inorganic materials 0.000 abstract 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004696 coordination complex Chemical class 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000003068 molecular probe Substances 0.000 abstract 1
- 239000012217 radiopharmaceutical Substances 0.000 abstract 1
- 150000003495 technetium Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20063300P | 2000-04-28 | 2000-04-28 | |
| PCT/US2001/013550 WO2001083436A2 (en) | 2000-04-28 | 2001-04-27 | Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6968301A true AU6968301A (en) | 2001-11-12 |
Family
ID=22742530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6968301A Pending AU6968301A (en) | 2000-04-28 | 2001-04-27 | Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
| AU2001269683A Ceased AU2001269683B2 (en) | 2000-04-28 | 2001-04-27 | Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001269683A Ceased AU2001269683B2 (en) | 2000-04-28 | 2001-04-27 | Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7321027B2 (enExample) |
| EP (1) | EP1276718B1 (enExample) |
| JP (1) | JP5186075B2 (enExample) |
| AT (1) | ATE359998T1 (enExample) |
| AU (2) | AU6968301A (enExample) |
| CA (1) | CA2407592C (enExample) |
| DE (1) | DE60127951T2 (enExample) |
| WO (1) | WO2001083436A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515131B2 (en) | 2000-02-22 | 2003-02-04 | Biostream Therapeutics, Inc. | Imagining agents for diagnosis of Parkinson's disease |
| WO2004043380A2 (en) * | 2002-11-08 | 2004-05-27 | President And Fellows Of Harvard College | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| JP2009051784A (ja) * | 2007-08-28 | 2009-03-12 | Inst Nuclear Energy Research Rocaec | 癌を抑制する放射性物質及びその調整方法 |
| WO2010144891A1 (en) * | 2009-06-13 | 2010-12-16 | President And Fellows Of Harvard College | Compositions and methods for imaging tissues, organs and tumors |
| US10550139B2 (en) | 2014-06-09 | 2020-02-04 | Triad National Security, Llc | Polydentate ligands and their complexes for molecular catalysis |
| WO2015191505A1 (en) * | 2014-06-09 | 2015-12-17 | Los Alamos National Security, Llc | Polydentate ligands and their complexes for molecular catalysis |
| WO2015200187A1 (en) | 2014-06-27 | 2015-12-30 | Reiley Pharmaceuticals, Inc. | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging |
| EP3242688B1 (en) | 2015-01-09 | 2020-01-29 | Reiley Pharmaceuticals, Inc. | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers |
| WO2017019664A1 (en) | 2015-07-28 | 2017-02-02 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2017223428A1 (en) | 2016-06-24 | 2017-12-28 | Cornell University | Rhenium complexes and methods of use for treating cancer |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| US10487100B1 (en) | 2017-04-04 | 2019-11-26 | Triad National Security, Llc | Macrocyclic ligands and their complexes for bifunctional molecular catalysis |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| WO2023009442A1 (en) * | 2021-07-26 | 2023-02-02 | Rapid Therapeutic Sciences Laboratories, Inc. | Improved process for ph-balanced cbg (# 10) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4638051A (en) * | 1984-04-30 | 1987-01-20 | The Johns Hopkins University | Brain imaging radiopharmaceuticals |
| ZA852981B (en) * | 1984-04-30 | 1985-11-27 | Univ Johns Hopkins | Brain imaging radiopharmaceuticals |
| US5136038A (en) * | 1984-07-19 | 1992-08-04 | University Of Florida | Radiopharmaceuticals and chelating agents useful in their preparation |
| ZA863205B (en) * | 1985-05-01 | 1987-08-26 | Univ New York State Res Found | Diagnostic radiopharmaceutical compounds |
| JPH02180865A (ja) * | 1987-12-29 | 1990-07-13 | Nippon Mejifuijitsukusu Kk | キレート形成性化合物とその用途 |
| AU3778989A (en) * | 1988-04-29 | 1989-11-29 | Mallinckrodt, Inc. | Diaminedithiol chelating agents for radiopharmaceuticals |
| US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
-
2001
- 2001-04-27 AU AU6968301A patent/AU6968301A/xx active Pending
- 2001-04-27 DE DE60127951T patent/DE60127951T2/de not_active Expired - Lifetime
- 2001-04-27 WO PCT/US2001/013550 patent/WO2001083436A2/en not_active Ceased
- 2001-04-27 CA CA2407592A patent/CA2407592C/en not_active Expired - Fee Related
- 2001-04-27 AU AU2001269683A patent/AU2001269683B2/en not_active Ceased
- 2001-04-27 AT AT01948207T patent/ATE359998T1/de not_active IP Right Cessation
- 2001-04-27 EP EP01948207A patent/EP1276718B1/en not_active Expired - Lifetime
- 2001-04-27 JP JP2001580865A patent/JP5186075B2/ja not_active Expired - Fee Related
-
2002
- 2002-10-23 US US10/279,214 patent/US7321027B2/en not_active Expired - Fee Related
-
2008
- 2008-01-21 US US12/017,328 patent/US20080226550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60127951D1 (de) | 2007-05-31 |
| WO2001083436A2 (en) | 2001-11-08 |
| EP1276718B1 (en) | 2007-04-18 |
| ATE359998T1 (de) | 2007-05-15 |
| JP2004501093A (ja) | 2004-01-15 |
| US20080226550A1 (en) | 2008-09-18 |
| AU2001269683B2 (en) | 2006-12-21 |
| US7321027B2 (en) | 2008-01-22 |
| JP5186075B2 (ja) | 2013-04-17 |
| DE60127951T2 (de) | 2008-01-17 |
| EP1276718A2 (en) | 2003-01-22 |
| WO2001083436A3 (en) | 2002-06-20 |
| US20040097735A1 (en) | 2004-05-20 |
| CA2407592C (en) | 2011-03-22 |
| CA2407592A1 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6968301A (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tumors | |
| Kiess et al. | Prostate-specific membrane antigen as a target for cancer imaging and therapy | |
| PT1472541E (pt) | Agentes de imagiologia e métodos de imagiologia de naaladase de psma | |
| Vaughn et al. | Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44 | |
| Price et al. | H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy | |
| Yazdani et al. | A bone-seeking trans-cyclooctene for pretargeting and bioorthogonal chemistry: a proof of concept study using 99mTc-and 177Lu-labeled tetrazines | |
| Smith-Jones et al. | Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1, 4, 8, 11-tetraazacyclotetradec-1-yl) methyl] benzoic acid | |
| Nichols et al. | 68 Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers | |
| Okarvi | Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview | |
| WO2002087498A3 (en) | Diagnostic imaging compositions, their methods of synthesis and use | |
| IL131386A0 (en) | Method for the detection and localization of malignant human tumours | |
| CA3027920C (en) | Modified dextran conjugates comprising a lysine-urea-glutamate pharmacophore | |
| Mojarrad et al. | Novel radiopharmaceutical (Technetium-99m)-(DOTA-NHS-ester)-Methionine as a SPECT-CT tumor imaging agent | |
| Melis et al. | Bifunctional chelators for radiorhenium: past, present and future outlook | |
| IL175667A (en) | Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it | |
| WO2004043380A3 (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors | |
| Sobral et al. | Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy | |
| NO20051811D0 (no) | Conjugates of TC complexes and targeting moiettes and their use in mri diagnostic | |
| Larenkov et al. | Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development | |
| PL365279A1 (en) | Biotin-derivates and their conjugates with chelating agents | |
| JP2002516882A5 (enExample) | ||
| AU2000263935A1 (en) | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy | |
| Lee et al. | Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with 177Lu for potential use in radioimmunotherapy | |
| ID28035A (id) | Kegunaan turunan antrasiklin untuk pengobatan tumor hati | |
| Vallabhajosula | Metal Radionuclides for Molecular Imaging |